Medical Care

Global Cancer CDK Inhibitors Market Research Report 2024

A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.
The global Cancer CDK Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
These inhibitors specifically inhibit CDK4/6 and show limited toxicity to normal cells. There are three FDA-approved CDK4/6 inhibitors and they are Palbociclib produced by Pfizer, Ribociclib produced by Novartis and Abemaciclib produced by Eli Lilly.
This report aims to provide a comprehensive presentation of the global market for Cancer CDK Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer CDK Inhibitors.
Report Scope
The Cancer CDK Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer CDK Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer CDK Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Eli-Lilly
Segment by Type
CDK4/6
CDK2
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer CDK Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer CDK Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CDK4/6
1.2.3 CDK2
1.3 Market by Application
1.3.1 Global Cancer CDK Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer CDK Inhibitors Market Perspective (2019-2030)
2.2 Cancer CDK Inhibitors Growth Trends by Region
2.2.1 Global Cancer CDK Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer CDK Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Cancer CDK Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Cancer CDK Inhibitors Market Dynamics
2.3.1 Cancer CDK Inhibitors Industry Trends
2.3.2 Cancer CDK Inhibitors Market Drivers
2.3.3 Cancer CDK Inhibitors Market Challenges
2.3.4 Cancer CDK Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer CDK Inhibitors Players by Revenue
3.1.1 Global Top Cancer CDK Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Cancer CDK Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Cancer CDK Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer CDK Inhibitors Revenue
3.4 Global Cancer CDK Inhibitors Market Concentration Ratio
3.4.1 Global Cancer CDK Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer CDK Inhibitors Revenue in 2023
3.5 Cancer CDK Inhibitors Key Players Head office and Area Served
3.6 Key Players Cancer CDK Inhibitors Product Solution and Service
3.7 Date of Enter into Cancer CDK Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer CDK Inhibitors Breakdown Data by Type
4.1 Global Cancer CDK Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Cancer CDK Inhibitors Forecasted Market Size by Type (2025-2030)
5 Cancer CDK Inhibitors Breakdown Data by Application
5.1 Global Cancer CDK Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Cancer CDK Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer CDK Inhibitors Market Size (2019-2030)
6.2 North America Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer CDK Inhibitors Market Size by Country (2019-2024)
6.4 North America Cancer CDK Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer CDK Inhibitors Market Size (2019-2030)
7.2 Europe Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer CDK Inhibitors Market Size by Country (2019-2024)
7.4 Europe Cancer CDK Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer CDK Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Cancer CDK Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer CDK Inhibitors Market Size (2019-2030)
9.2 Latin America Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer CDK Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Cancer CDK Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer CDK Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cancer CDK Inhibitors Introduction
11.1.4 Pfizer Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Cancer CDK Inhibitors Introduction
11.2.4 Novartis Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Eli-Lilly
11.3.1 Eli-Lilly Company Detail
11.3.2 Eli-Lilly Business Overview
11.3.3 Eli-Lilly Cancer CDK Inhibitors Introduction
11.3.4 Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.3.5 Eli-Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Cancer CDK Inhibitors Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of CDK4/6
Table 3. Key Players of CDK2
Table 4. Global Cancer CDK Inhibitors Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Cancer CDK Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Cancer CDK Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Cancer CDK Inhibitors Market Share by Region (2019-2024)
Table 8. Global Cancer CDK Inhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Cancer CDK Inhibitors Market Share by Region (2025-2030)
Table 10. Cancer CDK Inhibitors Market Trends
Table 11. Cancer CDK Inhibitors Market Drivers
Table 12. Cancer CDK Inhibitors Market Challenges
Table 13. Cancer CDK Inhibitors Market Restraints
Table 14. Global Cancer CDK Inhibitors Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Cancer CDK Inhibitors Market Share by Players (2019-2024)
Table 16. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2023)
Table 17. Ranking of Global Top Cancer CDK Inhibitors Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Cancer CDK Inhibitors Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Cancer CDK Inhibitors Product Solution and Service
Table 21. Date of Enter into Cancer CDK Inhibitors Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Cancer CDK Inhibitors Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Cancer CDK Inhibitors Revenue Market Share by Type (2019-2024)
Table 25. Global Cancer CDK Inhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Cancer CDK Inhibitors Revenue Market Share by Type (2025-2030)
Table 27. Global Cancer CDK Inhibitors Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Cancer CDK Inhibitors Revenue Market Share by Application (2019-2024)
Table 29. Global Cancer CDK Inhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Cancer CDK Inhibitors Revenue Market Share by Application (2025-2030)
Table 31. North America Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Cancer CDK Inhibitors Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Cancer CDK Inhibitors Product
Table 49. Pfizer Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Novartis Company Detail
Table 52. Novartis Business Overview
Table 53. Novartis Cancer CDK Inhibitors Product
Table 54. Novartis Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Eli-Lilly Company Detail
Table 57. Eli-Lilly Business Overview
Table 58. Eli-Lilly Cancer CDK Inhibitors Product
Table 59. Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
Table 60. Eli-Lilly Recent Development
Table 61. Research Programs/Design for This Report
Table 62. Key Data Information from Secondary Sources
Table 63. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer CDK Inhibitors Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cancer CDK Inhibitors Market Share by Type: 2023 VS 2030
Figure 3. CDK4/6 Features
Figure 4. CDK2 Features
Figure 5. Global Cancer CDK Inhibitors Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Cancer CDK Inhibitors Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Cancer CDK Inhibitors Report Years Considered
Figure 10. Global Cancer CDK Inhibitors Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Cancer CDK Inhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Cancer CDK Inhibitors Market Share by Region: 2023 VS 2030
Figure 13. Global Cancer CDK Inhibitors Market Share by Players in 2023
Figure 14. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Cancer CDK Inhibitors Revenue in 2023
Figure 16. North America Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Cancer CDK Inhibitors Market Share by Country (2019-2030)
Figure 18. United States Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Cancer CDK Inhibitors Market Share by Country (2019-2030)
Figure 22. Germany Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2019-2030)
Figure 30. China Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Cancer CDK Inhibitors Market Share by Country (2019-2030)
Figure 38. Mexico Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Cancer CDK Inhibitors Market Share by Country (2019-2030)
Figure 42. Turkey Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Pfizer Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
Figure 45. Novartis Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
Figure 46. Eli-Lilly Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies